Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13864615 | 0.86 | PIM1 (0.41) | PIM1CHEK2KDRPIM2P2RX3 | |
| SCHEMBL10292807 | 0.81 | SCN9A (0.33) | HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL8012000 | 0.79 | PIM1 (0.42) | PIM1CHEK2KDRPIM2P2RX3 | |
| Hydrochloric Acid SCHEMBL1070043 | 0.78 | PIM1 (0.42) | PIM1CHEK2KDRPIM2P2RX3 | |
| SCHEMBL8012008 | 0.78 | PIM1 (0.44) | PIM1CHEK2KDRPIM2P2RX3 | |
| Hydrochloric Acid SCHEMBL1072259 | 0.77 | PIM1 (0.43) | PIM1CHEK2KDRPIM2P2RX3 | |
| SCHEMBL8010656 | 0.76 | UCHL1 (0.40) | P2RX3 | |
| SCHEMBL881966 | 0.76 | PIM1 (0.44) | PIM1CHEK2KDRPIM2P2RX3 | |
| SCHEMBL8257072 | 0.76 | PIM1 (0.44) | PIM1CHEK2KDRPIM2HPGD | |
| SCHEMBL16077806 | 0.76 | PIM1 (0.39) | PIM1CHEK2KDRPIM2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8324155-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8211891-B2 | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211891-B2 | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2009134987-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| WO-2009064975-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, DPP4, SPINT2 | PIM1 1143/4885CHEK2 3679/4885KDR 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.